Losartan for Patients With COVID-19 Requiring Hospitalization

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Corona Virus InfectionAcute Respiratory Distress SyndromeSARS-CoV Infection
Interventions
DRUG

Losartan

Losartan; 50 mg daily; oral administration

OTHER

Placebo

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

Trial Locations (13)

30303

Grady Memorial Hospital, Atlanta

32209

University of Florida Health Jacksonville, Jacksonville

32611

University of Florida Health Gainesville, Gainesville

39216

University of Mississippi Medical Center, Jackson

45267

University of Cincinnati Medical Center, Cincinnati

48202

Henry Ford Hospital, Detroit

55337

M Health Fairview Ridges Hospital, Burnsville

55415

Hennepin County Medical Center, Minneapolis

55422

North Memorial Health Hospital, Robbinsdale

55435

M Health Fairview Southdale Hospital, Edina

55455

M Health Fairview University of Minnesota Medical Center, Minneapolis

University of Minnesota, Minneapolis

08103

Cooper University Hospital, Camden

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Minnesota

OTHER

NCT04312009 - Losartan for Patients With COVID-19 Requiring Hospitalization | Biotech Hunter | Biotech Hunter